Bridging Pharmaceutical Challenges and Technology: Innovative Formulation and Analysis of Telmisartan

 

 

Figure 1: Mechanism of action of Telmisartan

However, from a pharmaceutical point of view, there are some challenges that impact the preparation of telmisartan. From a Biopharmaceuticals Classification System point of view, the drug is considered a BCS class II drug because of its high permeability and very low water solubility. The bioavailability of telmisartan is differentiated because of its low solubility in a wide range of physiological pH. There is a requirement to develop an innovative drug delivery system to increase its solubility.^[2]

Numerous research studies have been conducted in the last few years, specifically between 2020 and 2025, to devise innovative solutions to counter the biopharmaceutical issues of telmisartan. Solid dispersions, nanocrystals, lipid formulations, fast-dissolving oral films, nanoparticles, and SMEDDS have played a significant role in improving the dissolution and oral bioavailability of the drug. Drug delivery systems not only help improve the solubilization of the drug but also help improve drug compliance.^[3]

The establishment of efficient analytical methods is a very important factor in the efficacy, safety, and quality of telmisartan pharmaceuticals, concurrently with the formulation development process. Stability-indicative HPLC methods, LC/MS/MS bioanalysis, and sophisticated solid characterization methods are considered highly valuable in formulation development and pharmacokinetic studies. More recently, cost-effective analytical methods, as well as green analytical chemistry, also come into consideration.^[4]

The aim and objective of the current review article are to provide a comprehensive pharmaceutical analysis of Telmisartan. This has been accomplished by referring to some of the new developments in the formulation that have entered the field from the year 2020-25, pointing out some of the key concerns that have emerged with regard to the physicochemical and biopharmaceutical aspects of the drug, and finally referring to some of the developments that have entered the field of qualitative and quantitative analysis. The amalgamation of formulation technology and analytical technology has assisted the current review in providing the reader with a fresh perspective about the present and future trends related to Telmisartan.

In the current short period, there has also been emphasis on innovative approaches in the formulation delivery of the drug substance, such as telmisartan, based on the concept of patient-friendly formulation forms with improved drug bioavailability, particularly in patients who lack drug compliance and have difficulty in swallowing the drug. Therefore, the most effective method is the combination of innovative technique with conventional analytical approaches with the objective of smooth operation in the development process. ^[5]

2. SOLID-STATE AND SOLUBILITY CHALLENGES OF TELMISARTAN

Telmisartan is a weak acid and a lipophilic drug. The complexity of Telmisartan’s chemical nature explains the extent to which the potency of the drug is affected. The molecular weight of Telmisartan is approximately 514.6g/mol. Telmisartan contains a biphenyl and a benzimidazole moiety, which are highly responsible for the hydrophobicity. The high partition coefficient of Telmisartan with a log P=7 has a great impact on the permeability and solubility properties of the drug, which highly favors the permeability properties rather than the solubility properties. Telmisartan falls under the second class in the proposed BPS theory. Telmisartan has high permeability and low solubility.^[6]

From the physicochemical properties point of view, it can be classified as a substance with very poor solubility in the pH range of body fluids, that is, pH 1-9. The poor solubility of telmisartan in the stomach fluids compared to weak bases, in which the solubility increases with a decrease in pH, indicates the dissolution rate-limited absorption of telmisartan. The poor solubility of the active substance is because of the pH-independent nature of the substance, for which the classical formulation does not permit the optimal bioavailability.^[7]

The solid state properties make the formulation of Telmisartan slightly more complicated. The drug is mostly present in the form of crystals, which have poor dissolution properties and wettability. Amorphous solids have better solubility properties but are not stable and can revert back to crystals. Crystal form and polymorphism can be used to improve stability, uniformity, and dissolution properties. Thus, there is a need for a thorough study of the solid state properties of the drug during the formulation process. ^[8]

Telmisartan has high permeability in biopharmaceutical classification, which is beneficial for effective transcellular transport after dissolution. It has low oral bioavailability (~40-50%) due to low solubility and some gastrointestinal problems; food can influence its absorption, depending on the formulation, which is again one of the factors in the discussion of bioequivalence and educating a patient. The presence of high protein binding (>99.5%) in plasma would help in determining its distribution, but its permeability is not affected.^[9]

The possibilities of producing a metabolic interaction with other medications are very low, taking into consideration that the drug is a substrate for the P450 enzymes. On the other hand, the route of elimination of Telmisartan, which is the intact hepatic first-pass metabolism, is limited. However, the dissolution rate is a very important factor as a core rate-determining step in the bioavailability of the drug. In order to improve the effects of the treatment, the design formulation is a very important factor in improving the wettability and the required solubility. In addition to this, Telmisartan has a large crystal lattice energy in addition to poor wettability properties, thus hindering the breakdown of the drug into stomach fluid.^[10]

It is highly lipophilic and thus very effective in permeation, but the tendency to cause dispersion problems and aggregation in the aqueous medium is a limitation to it. The intra-person variability in rate is shown to some extent by the variations in pH and motility of the gastro-intestine. The primary target in the development process at present in pharmacy is the enhancement of solubility and water dissolution rate of the drug substance telmisartan.^[11]

3. Pharmaceutical Challenges in Telmisartan Formulation

The undesirable physicochemical property of telmisartan is the major reason for its formulation difficulties. The low water solubility of the compound over a wide range of physiological pH values is one of the major problems existing in this compound.^[12] Telmisartan has pH-independent low solubility, which leads to an absorption, limited by dissolution, after oral administration compared to the solubility of weakly basic drugs, which dissolve readily in the acidic fluid in the stomach. Bioavailability after oral administration is directly affected by this property of the compound.^[13]

High lipophilicity along with the crystalline form of telmisartan leads to another major issue. The dispersion of the drug in the aqueous part of the gastrointestinal tract gets affected due to high crystal lattice energy along with the absence of wettability, leading to poor dissolution. However, the amorphous form of telmisartan has high solubility; it tends to undergo a recrystallization process when stored. It also remains thermodynamically unstable. The maintenance of physical stability in these formulations still remains a topmost priority in drug development.^[14]

Due to low and irregular oral absorption, the optimization of formulation in Telmisartan is relatively more difficult. Although the drug has high permeability in the gastrointestinal tract, the absorption of the drug is limited by a low dissolution rate rather than the rate of transfer across the membranes. However, it is difficult to maintain a constant level of the drug in the bloodstream and its bio-equivalence when administered in a conventional formulation due to individual variations in gastrointestinal motility, bile salt concentrations, and the presence or absence of food in the system.^[15]

In addition, the formulation processing and excipient interaction of telmisartan are also being investigated. In an effort to further improve solubility, the addition of surfactants, polymer matrices, or alkalizing agents may cause chemical instability, precipitation upon dilution, and variability of concentrations. Sustaining particle size, inhibiting agglomeration, and maintaining consistency of large-scale formulations would be a great challenge in advanced delivery in nanocrystal formulations, solid dispersions, and lipid formulations.^[16]

In addition, the formulation of telmisartan concerning stability and regulatory requirements should also be taken into consideration. Because of the Solid State Transition and moisture sensitivity of the drug substance, the stability at fast and extended states may pose a challenge, especially in the tropics. The IVIVC and stability-indicating analytical procedures have a great importance in the approval of bio equivalency, especially for new formulations of delivery that would contribute to the challenges and expenses of development.^[17]

4. FORMUALTION STRATEGIES FOR TELMISARTAN

The poor water solubility and dissolution rate-limited absorption of Telmisartan have led to a lot of interest in the development of complex formulation technology that can increase the bioavailability and therapeutic utility of the drug. The primary aim of the approaches that have been reported from the year 2020 to 2025 is to improve the solubility, dissolving rate, and physical stability with less effect on patient compliance and acceptance.

4.1 Hydrophilic Matrix Sustain

Among the techniques that have been most widely explored for telmisartan, the use of solid dispersions has been prominent. This technique involves the molecular dispersion of telmisartan in hydrophilic polymer matrices like poloxamers, Soluplus®, polyvinylpyrrolidone (PVP), or polyethylene glycol (PEG). The technique has been observed to enhance the perception of solubility, the reduction of crystallinity, and the improvement of wettability, which when combined, result in faster dissolution rates. When compared to the conventional crystalline formulation of drugs, it has been observed that amorphous solid dispersions have been discovered to significantly enhance the solubility of telmisartan; however, the physical stability to prevent recrystallization is still a significant concern.^[18]

4.2 Nanocrystals and Polymeric Nanoparticle

Nanocrystal technology received considerable attention because of the dispersion of telmisartan. The reduction in particle size to the nanoscale range increases the rate of dissolution because of the rise in the surface area and saturated solubility. Telmisartan nanocrystals, which are surfactant-stabilized dispersions containing poloxamer 188, PVP, or TPGS, have been reported to have increased dissolution properties both in vitro and in vivo, along with increased bioavailability. Polymeric nanoparticles act as anti-aggregating agents with the ability of controlled drug release.

4.3 Lipid-Based Drug Delivery Systems

In Lipid formulations like nanoemulsions, solid lipid nanoparticles (SLN), and self-microemulsifying drug delivery systems (SMEDDS), there have been studies to counter the solubility problems of telmisartan. These formulations work on the principle of minimizing the effects of first-pass metabolism, maximizing the solubilization of the drug in the gastrointestinal fluids, and possibly maximizing its lymphatic transport. Telmisartan SMEDDS formulations have been reported to have improved oral absorption, self-emulsification, and dissolving abilities .

4.4 Rapidly Dissolving Oral Films &Orodispersible Films

For patients who are and dysphagic, fast-dissolving films and orodispersible tablets are proven alternative dosage forms to conventional tablets. Fast-dissolving films of Telmisartan and hydrophilic polymers such as pollutant and HPMC have the potential to dissolve rapidly in the mouth, thus accelerating the release of the drug and improving patient compliance. Moreover, these methods may also provide an initial absorption before gastric emptying and could thus reduce the variability of exposure to the drug.^[19]

4.5 Floating and Gastroretentive systems

Floating tablets, microspheres, and beads are a few examples of Gastro-retentive dosage forms that have been studied for the improvement of dissolution and extension of the Gastro-intestinal retention period. They are designed to provide a constant concentration of the drugs in the plasma and improve bioavailability.

4.6 Quality by Design (QbD) and Process Optimization

The use of design of experiments (DoE) and quality by design (QbD) strategies in optimizing process variables and formulation factors has also been recently preferred in the literature. This ensures regulatory harmony, scalability, and excellence in product performance.

4.7 Cyclodextrin Inclusion Complexes

To enhance the aqueous solubility and dissolution rate of telmisartan, cyclodextrins like β-cyclodextrin, hydroxypropyl-β-cyclodextrin (HP-β-CD), and sulfobutyl ether-β-cyclodextrin have been investigated. Inclusion complexes lead to an enhanced molecular encapsulation of the lipophilic drug, a decrease in crystallinity, and an improvement in wettability. Because of the safety profile and regulatory acceptability in oral dosage forms, inclusion.^[20]

4.8 Cocrystal Engineering

Pharmaceutical co-crystals are a novel method of solid drug formulation, especially for solid drug development, in which a crystal form of telmisartan is made up of certain pharmaceutically acceptable co-formers like nicotinamide, fumaric acid, and saccharin. The cocrystallization of telmisartan includes the co-crystalization process of telmisartan, which results in an increase in the crystal lattice.

4.9 Supersaturating Drug Delivery Systems (SDDS)

Supersaturating formulations are designed to attain and sustain the supersaturated condition of telmisartan for a short period in the GI tract fluid. Precipitation inhibitors HPMC-AS, PVP-VA, or Soluplus® have the ability to retard the precipitation of the solid and improve absorption. They are best applicable for BCS-Class II compounds with successful oral bioavailability enhancement results.

4.10 Mesoporous Silica-Based Drug Delivery

The mesoporous materials such as SBA-15 and MCM-41 have been studied as telmisartan delivery systems owing to their high surface area and pore size, which result in the drug being in the amorphous or nano-confined state. The drug delivery system improves the drug’s dissolution property and also prevents recrystallization, while at the same time having good physical stability and delivery properties.^[21]

4.11 Proliposomes and Liposomes

Formulations such as proliposomes, which form liposomes upon hydration, and conventional liposomes have been studied for the improvement of solubility and stability of telmisartan. These vesicular carriers encapsulate drugs in a lipid bilayer, thereby increasing the dispersibility of the drug in an aqueous medium. Of these, proliposomes have been found to be more stable than conventional liposomes.

4.12 Polymeric Micelles

Amphiphilic block copolymers such as Pluronic and Soluplus have the ability to self-assemble into nanoscale micellar structures in aqueous media, which can encapsulate drugs in the hydrophobic core of the micelles. These drug delivery systems have the ability to enhance solubilization, overcome aggregation issues, and provide improved dissolution and potential controlled release properties. The small size of the micelles and their ability to encapsulate drugs make them ideal candidates for oral delivery.

4.13 Hot-Melt Extrusion (HME) Technology

Hot melt extrusion is a non-solvent-based and viable method for the preparation of drugs such as Telmisartan in a solid dispersion form. It enhances the miscibility of the drug and polymer, reduces crystallinity, and enhances drug dissolution. HME is consistent with the QbD approach and also compatible with a continuous process.

4.14 Co-Amorphous Drug Systems

Co-amorphous formulations have been investigated as a mixture of low molecular weight excipients like amino acids or organic acids and the antihypertensive drug, telmisartan. There are many advantages of these systems regarding their solubility and dissolving capabilities, as well as their properties for physical stability compared to amorphous systems. These systems have slowly started gaining the attention of researchers as a new alternative to the conventional amorphous dispersion

5. ADVANCED FORMULATION TECHNOLOGIES

Because of the long-term problems related to the poor aqueous solubility and low dissolution-related absorption of telmisartan, there is a need to identify new and advanced formulation technologies that are not considered in conventional formulation strategies. The combination of nanotechnology, lipid science, and process design methodologies as a new approach for enhancing the biologic availability, stability, and pharmacologic activity of telmisartan formulations is emphasized in recent publications in the literature.^[22]

5.1 Nanocrystal and Nanosuspension

One of the most widely studied contemporary approaches for the improvement of telmisartan’s oral dosage form technology is nanocrystal technology. Nanocrystals offer a substantial improvement in surface area and solubility saturation because of the reduction in size of the drug particles to the nanoscale range, thereby increasing the rate of dissolution. Stabilized nanosuspensions of surfactants and polymers offer an increased rate of dissolution with little alteration in the chemical formulation as per the studies for the review of this research topic.^[23]

5.2 Advanced Lipid-Based Delivery Systems

The recent reviews on telmisartan have also discussed lipid-based drug delivery systems in detail, such as solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and self-nanoemulsifying drug delivery systems (SNEDDS). These systems help to decrease the variability of absorption by facilitating lymphatic transport and enhancing the solubilization of drugs in gastrointestinal fluids.^[24] Besides having a higher drug loading capacity and physical stability than conventional lipid systems, advanced lipid carriers are also applicable for highly lipophilic drugs like telmisartan.

5.3 Amorphous and Co-Amorphous Systems

The crystalline form led to the creation of amorphous forms as novel formulations of Telmisartan. Co-amorphous formulations provide improved physical stability over single-component amorphous formulations, including telmisartan stabilized with low molecular weight co-formers or polymers. The formulation provides improved apparent solubility and dissolution properties and prevents recrystallization during storage, as mentioned in review articles.

5.4 Nanocarriers Produced By Means Of Polymeric

Polymeric nanocarriers in the form of nanoparticles, nanocomposites, or poly- and lipid-based hybrids have also been explored as versatile carriers for delivery. As per different reviews, these delivery systems are efficient enough to protect telmisartan from the degradation effects of the environment, improve the dispersibility potential of the drug in an aqueous environment, or control the release rates of the drug molecules. In the oral delivery system, the combined potential of polymers and lipids in the hybrids is helpful.^[25]

5.5 Advanced Oral Thin Films and Buccal Technologies

Buccal delivery systems with advanced technology and fast-dissolving oral thin films are some of the recent developments in the dissolution of telmisartan that have a patient-friendly approach. According to a recent review of literature, these systems not only help in increasing the compliance of patients regarding the dosage, but partial absorption can also be achieved, which can reduce the first-pass effects and gastrointestinal variability. Solid dispersions and nanocrystal oral films have been proposed as a promising combination therapy.

5.6 Process-Driven Technologies & QbD

The use of process analytical technology and quality by design in advanced formulation development is being increasingly adopted. The use of quality by design in optimizing key critical formulation variables and ensuring batch-to-batch consistency has been emphasized in review articles. These approaches are very useful in complex telmisartan formulations involving lipid formulations or nanotechnology.^[26]

6. STABILITY STUDIES

Stability studies are a significant part of pharmaceutical research, as they offer crucial information regarding the physical, chemical, and microbiological stability of telmisartan and its dosage forms during the shelf life. Telmisartan is a crystalline drug with low solubility in water, apart from being sensitive to formulation variables; therefore, stability testing for the purpose of ensuring efficacy and safety and quality of the final product becomes a significant aspect.

6.1 Purpose of Stability Studies

The shelf life determination, selection of appropriate storage conditions, and identification of potential sites for degradation are the crucial objectives of the stability studies in telmisartan formulations. In the advanced delivery systems such as nanocrystals, lipid formulations, and amorphous solid dispersion, the stability studies have been very informative in formulation optimization, packaging selection, and regulatory approval.^[27]

6.2 Fire Hazard

Even if the chemical is stable over a wide pH range, stress conditions like heat, UV light, oxidizing agents, high acidity, and alkalinity could bring about degradation. The methods used to establish stability, particularly reverse-phase HPLC, are utilized to follow drug concentrations and quantify degradation. The significance of excipients, surfactants, and pH regulators to chemical stability is underscored in the literature review because of the potential impact these could have on degradation rates.

6.3 Physical Stability

The tendency of Telmisartan to exist in a crystalline state with poor solubility properties poses a major issue in terms of physical stability. The physical instability of amorphous solid dispersions and nanosized solid dispersions may reveal phase separation, agglomeration, and/or recrystallization upon storage. Particle size analysis, XPDIFF, and DSC are common techniques used to understand changes in crystallinity, thermal properties, and size changes of particles with storage conditions.

6.4 Stability in Advanced Delivery Systems

The newer formulations of telmisartan should be tested for their stability. For maintaining the formulations in lipid-based formulations, the following characteristics should be monitored: phase-separation, droplet size, and zeta potential. The formulations containing nanocrystals as well as nanoparticles will be tested for their sedimentation, aggregation, and ability to dissolve. The mechanical strength, homogeneity for drug content, and disintegration time for the fast-dissolving oral films should be tested in stability conditions.^[28]

6.5 Accelerated and Long-Term Stability Studies

According to the recommendations by ICH, stability testing of telmisartan formulations is generally conducted under accelerated and long-term conditions. Long-term studies confirm product stability under recommended storage conditions, whereas accelerated stability studies provide early information regarding degradation patterns and possible shelf-life limitations. Formulations intended for tropical regions require special attention, as high temperature and humidity can aggravate stability problems.

6.6 Packaging and Environmental Factors

Packaging plays an important role in maintaining the stability of telmisartan compositions. For hygroscopic and amorphous formulations, in particular, it is often recommended to use a moisture-protective package such as an aluminium-aluminium blister or a high-barrier container. In general, the review of the literature shows that light and moisture can have great influences on chemical and physical stability and hence the application of proper packaging techniques is essential. ^[29]

7. REGULATORY CONSIDERATION

In the production, approval, and commercialization of telmisartan drug formulation, regulatory considerations play a crucial role. This is because Telmisartan Products, which include a much-needed drug for patients with high blood pressure, should meet certain strict regulatory norms in order to ensure their therapeutic equality, quality, safety, and efficacy. Advanced or innovative drug delivery systems make regulatory considerations more complex.^[30]

7.1 Regulatory Classifications & Approvals

An example of a confirmed API for IR oral dosage formulations is telmisartan. Conventional generics normally follow the truncated approval process, which requires documentation of pharmaceutical and bioequivalency studies compared with the drug listed in the reference drug list. But because of differences in drug release or absorption characteristics, new or advanced formulations such as nanocrystals, lipid formulations, or oro-dispersible films may require additional attention.

7.2 Quality and Manufacturing Requirements

Telmisartan formulations need strict conformity with current Good Manufacturing Practice (cGMP), as stated by the authorities. Hydraulic phenomena like uniformity of batch-to-Batch, Excipient compatibility, Reprocessing, Raw material control can be covered by this. Manufacturers of advanced formulations need a clear identification of key material attributes as a requirement not only to ensure a specified product lifetime but also a specified product performance.^[31]

7.3 Bioequivalence and In Vivo Performance

In the Performance of bioequivalence studies is one of the important regulation requirements that apply to generic telmisartan preparations. Bioequivalence studies are needed because telmisartan preparations are considered to be dissolution-limited absorption products because of the gastrointestinal factors involved, thereby requiring carefully planned bioequivalence tests to address the variation that arises from the composition of the telmisartan formulations. More pharmacokinetic information or IVIVC studies may be required by the regulatory authority regarding any new delivery system or device.

7.4 Stability and Shelf-Life Requirements

Extensive stability studies are mandated by regulatory authorities to arrive at storage conditions and shelf life for telmisartan formulations. Accelerated and long-term stability studies shall provide information on whether it retains its physical properties, actives content, and ability to form solutions during its entire shelf life. Regulatory authorities may require better justification for stability and safe packaging methods for moisture-sensitive and amorphous formulations.^[32]

7.5 Validation Methods

It is a regulatory requirement that all analytical methods employed in quality control of telmisartan need to be validated. The use of stability-indicating methods, which help distinguish the drug from its degradation products, is particularly important. Other characterizations, such as a study of the solid state of the drug, may be requested by some regulatory jurisdictions for complex formulations.

7.6 Risk Based & QbD

The adoption of risk-based development methodologies and Quality by Design (QbD) is supported by current changes in regulations. Specifically, in complex telmisartan dosage forms, an increasing trend in regulatory requirements implies an understanding that requires a holistic approach toward formulation and process understanding. The application of QbD demonstrates improved regulatory review procedures due to an evident approach toward thorough development, reduction of risk, and effective product control.^[33]

 FUTURE PROSPECT

elmisartan is a very well-known antihypertensive drug; nevertheless, due to the challenging pharmacological properties of telmisartan, a significant amount of research interest for researchers engaged in pharmaceutical research remains associated with this drug. Future formulations are expected to focus on advanced and combined delivery systems whereby more than one solubility-improving approach will be combined for the development of co-amorphous formulations with improved physical stability, polymer and lipid hybrid nanoparticles for oral delivery, and nanocrystal-filled oral films.

An important area of the future is the way towards the application of patient-centered and customized medicine practices. The concept of personalized administration of Telmisartan may become a reality with emerging technologies such as 3D printing, flexible oral films, and adjustable dosing systems, particularly among geriatric and pediatric communities. The emphasis on improving the area of better therapeutic compliance is likely to bring about new developments in the area of orodispersible tablets and fast-dissolving dosage forms.^[34]

Future studies are also likely to be centered on in vitro–in vivo correlation (IVIVC), predictive dissolution studies, as well as real-time processing analyses via process analytical technology (PAT) in the analytical as well as the regulatory arena.^[35] Finally, the development of more sustainable, more effective, as well as more regulatory-compatible products for telmisartan will be facilitated by the application of the principles of Green Chemistry in analytical practice.^[36]

CONCLUSION

The key challenges to the development of telmisartan, a highly relevant angiotensin II receptor antagonist from a pharmacological point of view, are its low water solubility and dissolution-limited oral bioavailability. These issues have led to an immense body of research related to the development of new formulation technologies from a pharmaceutics point of view. Some examples of these are solid dispersion, nanocrystal technologies, lipid-based delivery systems, fast-dissolvable oral films, and highly complex nanoparticulate systems. Improving its solubility, stability, and pharmacological effects have been demonstrated to be highly possible with the use of new formulation technologies.

On the other hand, robust and scientifically ascertained analytical tools play a crucial role in ensuring the quality, safety, and compliance of telmisartan formulations. The importance of systematic, science-driven development procedures in telmisartan formulations can also be appreciated in the context of stability studies or related regulatory issues. Taking everything into account, a complete approach toward overcoming the biopharmaceutical hurdles in telmisartan can thus be obtained using an integrated formulation science approach in a related formulation development program. It could be expected that progress would also be made in patient-centric formulations, along with advanced delivery systems, offering a boost to clinical efficacy for telmisartan formulations.

REFERENCES

1. Shah N. Solubility and dissolution rate enhancement of poorly soluble telmisartan using hydrotropy method. Asian J Pharm. 2024;18(1). doi:10.22377/ajp.v18i01.5272.
2. Kaushik R, Verma R, Budhwar V, Kaushik D. Investigation of solid dispersion approach for the improvement of pharmaceutical characteristics of telmisartan using central composite design. Int J Appl Pharm. 2023;15(5).
3. Kunam V, Garikapati DR, Suryadevara V, et al. Solubility and dissolution rate enhancement of telmisartan by solid dispersion and pelletization technique using Soluplus as carrier. Int J Appl Pharm. 2020;12(1). doi:10.22159/ijap.2020v12i1.35620.
4. Aziz HA, Al-Akkam EJ. Preparation and evaluation of telmisartan solid dispersion as sublingual tablets. J Fac Med Baghdad. 2024;65(4). doi:10.32007/jfacmedbagdad.2145.
5. Gupta S, Dubey V. Development and optimization of telmisartan-loaded polymeric nanoparticles: A novel approach for enhanced drug delivery and sustained release. Int J Pharm Life Sci. 2025;16(6):1-7. doi:10.64149/ijpls.16.6.1-7.
6. Alalaiwe A, Mahgoub H, Salawi A. Nanocrystal technology for poorly soluble drugs: Recent advances and formulation challenges. Pharmaceutics. 2021;13(9):1357.
7. Aldeeb RA, El-Miligi MF, El-Nabarawi M, Tag R, Amin HMS, Taha AA. Enhancement of the solubility and dissolution rate of telmisartan by surface solid dispersions employing superdisintegrants and hydrophilic polymers. Scientia Pharm. 2022;90(4):71.
8. Khan S, Rizvi SAA, Bhatnagar A. Solid dispersion-based solubility enhancement of telmisartan using hydrophilic polymers. ACS Omega. 2021;6(12):8125-8136. doi:10.1021/acsomega.1c00422.
9. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: Importance and enhancement techniques. ISRN Pharm. 2020;2020:1-10.
10. Eswarudu MM, Roja P. An updated review on analytical methods for estimation of azelnidipine and telmisartan. Asian J Pharm Res Dev. 2023;10(2):1108.
11. Dressman JB, Reppas C. Dissolution, bioavailability, and IVIVC for BCS class II drugs: Implications for formulation development. Eur J Pharm Sci. 2020;150:105354.
12. Uthumansha U, Prabahar K, Gajapathy DB, El-Sherbiny N, Elsherbiny M, Qushawy M. Optimization and in vitro characterization of telmisartan loaded sodium alginate beads for improved biopharmaceutical properties. Pharmaceutics. 2023;15(2):709. doi:10.3390/pharmaceutics15020709.
13. Ha ES. Effect of process parameters on nano-microparticle formulation of telmisartan: Nanotechnology approaches to overcome poor solubility. Pharmaceutics. 2024;16(12):1508.
14. Giri BR, Kwon J, Vo AQ, Bandari S, et al. Hot-melt extruded amorphous solid dispersion for solubility, stability, and bioavailability enhancement of telmisartan. Pharmaceuticals. 2021;14(1):73. doi:10.3390/ph14010073.
15. Kumar VA, Rada SK. QbD approach in the enhancement of oral bioavailability of telmisartan fast dissolving tablets employing starch humate as a new superdisintegrant. Int J Appl Pharm. 2025;17(2):468-482. doi:10.22159/ijap.2025v17i2.52865.
16. Potti L, Avula PR. Orodispersible tablets of telmisartan through cyclodextrin-surfactant complexation: A quality by design approach. J Res Pharm. 2025;26(5):1202-1213.
17. Jaiswal P, Aggarwal G, Harikumar SL, Singh K. Development of self-microemulsifying drug delivery system and solid-self-microemulsifying drug delivery system of telmisartan. Int J Pharm Investig. 2025.
18. Pachpute TS, Shirbhate MP, Badhe PD, Pawar TV, Shinde MB, Rajaram NA. Development and characterization of telmisartan orodispersible films: Overcoming solubility challenges for enhanced hypertensive therapy. Int J Environ Sci. 2025;11(16s):2322-2331. doi:10.64252/sm2qsd39.
19. Alvarez-Rodriguez M, Blanco-Prieto MJ, Torres Darias R. Nanotechnology strategies to improve oral bioavailability of poorly soluble drugs: A review. Pharmaceutics. 2021;13(9):1289.
20.  Kommuru TR, Gurley BK, Khan MA, Reddy IK. Self-nanoemulsifying drug delivery systems (SNEDDS): Formulation principles and recent advances in oral delivery. Pharmaceutics. 2022;14(3):711.
21. Müller RH, Shegokar R, Keck CM. 20 years of lipid nanocarriers: Has the promise been delivered? Pharmaceutics. 2023;15(1):111.
22. Nnamani PO, Kenechukwu FC, Attama AA. Co-amorphous systems for poorly soluble drugs: Formulation strategies and physicochemical considerations. Pharmaceutics. 2021;13(3):342.
23. Yin L, Zhao Y, Gao P, Wang J. Polymeric micelles and hybrid drug delivery systems as effective strategies for oral delivery of poorly soluble drugs: A review. Front Chem. 2024;12:987654.
24. Venkatesh G, Saravanan M, Sarath CVH. Stability considerations and challenges in amorphous solid dispersion systems: A review. J Pharm Sci Res. 2021;13(4):1867-1875.
25. Ghosh AK, Kumar A, Singh S. Recent analytical and formulation stability trends for challenging drugs: A review. J Drug Deliv Sci Technol. 2022;71:103199.
26.  Raval NS, Patel BR. Accelerated and long-term stability study designs in pharmaceutical development: A review. J Pharm Innov. 2023;18:742-756.
27. Duarte JG, Duarte MG, Piedade AP, Mascarenhas-Melo F. Rethinking pharmaceutical industry with Quality by Design: Application in research, development, manufacturing, and quality assurance. AAPS J. 2025;27:96. doi:10.1208/s12248-025-01079.
28. BMC Med Res Methodol. Bioequivalence trials for the approval of generic drugs in Saudi Arabia: A descriptive analysis of design aspects. 2024;24:82. doi:10.1186/s12874-024-02207-4.
29. Front Med. Editorial: Regulatory science and meta science as components of regulation of medical products and practices. 2025;12:1664402. doi:10.3389/fmed.2025.1664402.
30. Saleh-Bey-Kinj Z, Heller Y, Socratous G, Christodoulou P. 3D printing in oral drug delivery: Technologies, clinical applications and future perspectives in precision medicine. Pharmaceuticals. 2025;18(7):973. doi:10.3390/ph18070973.
31. Rodriguez GYG, González Díaz CM, Dahiya S. Personalized medicine: Perspectives on innovations and challenges in 3D printing, continuous manufacturing and on-demand production. Discov Pharm Sci. 2025;1:10. doi:10.1007/s44395-025-00011-7.
32. García-Arieta A, et al. A survey of regulatory recommendations for waivers of in vivo bioequivalence studies of generic products for certain dosage forms. J Pharm Pharm Sci. 2025;28:14721.
33. Patel D, Shah M, Jogani V. Nanocrystal-based drug delivery systems for poorly soluble drugs: Formulation approaches and stability aspects. Drug Dev Ind Pharm. 2022;48(5):621-635.
34. Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2021;86(3):215-223.
35. Patel VR, Agrawal YK. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res. 2020;2(2):81-87.
36. Chavda VP, Patel AB, Mistry KJ, Vaghasiya DD. Quality by design approach in pharmaceutical product development: Recent advances and applications. Curr Pharm Des. 2024;30(4):455-469.